Upgrade Now

Glaxo, Sanofi pledge 200m Covid doses to global facility

By Frank Prenesti

Date: Wednesday 28 Oct 2020

(Sharecast News) - Pharmaceutical companies GlaxoSmithKline and Sanofi said they had agreed to make 200m doses of their potential Covid-19 vaccine to a worldwide pooled facility.
The two firms started a phase 1/2 study for the vaccine in September with a total of 440 subjects enrolled. First results from the study are expected in early December, to support the initiation of a phase 3 study before the end of the year.

If data is sufficient for license application, the companies intend to seek regulatory approvals for the vaccine from the first half of 2021 ad have scaled up manufacturing of the antigen and adjuvant.

The facility is run by Covax, a global risk-sharing collaboration run by Gavi, the Coalition for Epidemic Preparedness Innovations and World Health Organisation. More than 180 nations have signed up to get timely and cost-effective access to Covid-19 vaccines.

"The commitment we are announcing today for the Covax facility can help us together stand a better chance of bringing the pandemic under control," said Thomas Triomphe, executive vice-president and global head of Sanofi Pasteur.


Email this article to a friend

or share it with one of these popular networks:

Top of Page